Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
UV spectrum of TPE-DCV in the detection medium shows an absorption band at 409 nm (Figure S5)
Their typical release profile involves an abrupt and non-specific drug release, which cannot be modulated in response to localized physiological cues, thereby compromising therapeutic efficacy and increasing the potential for adverse effects
doi: 10.1002/hep.30359 62
Contraindications: Not for use in individuals with cancer, during pregnancy/breastfeeding, or those with known hypersensitivity to peptide components
Emulsifiers help stabilize a product
78 HP 160 CAGRILINTIDE Long-Acting Amylin Analog ALIASES Cagrilintide, AM833, long-acting amylin analog CLASS Synthetic amylin analog once-weekly dual amylin/calcitonin agonist FORMULA CHNO (approx) SEQUENCE 37-residue amylin analog with C20-fatty-acid albumin tether HALF-LIFE ~7 days (once-weekly dosing) ROUTES Subcutaneous (Phase 2/3 clinical) MECHANISM OF ACTION Long-acting amylin analog
US$ 22.20
US$ 20.42
US$ 21.09
US$ 28.99
